Teriparatide

Source / Derivation:

Teriparatide is a synthetic peptide corresponding to the first 34 amino acids of human parathyroid hormone (PTH 1-34). It is designed to replicate the anabolic effects of endogenous PTH on bone formation while maintaining safety and efficacy for clinical use.

Teriparatide

Mechanism of Action:

Teriparatide binds to parathyroid hormone receptors (PTH1R) on osteoblasts, stimulating bone formation, increasing osteoblast activity, and enhancing calcium deposition. Intermittent administration preferentially promotes an anabolic response, improving bone density and strength.

Clinical Relevance & Potential Outcomes:

Clinical studies indicate Teriparatide may support increased bone mineral density, reduced fracture risk, and improved skeletal strength, particularly in patients with osteoporosis or high fracture risk. It is considered a key therapeutic option for anabolic bone therapy.

Intended Clinical Application:

Teriparatide may be relevant for patients requiring enhanced bone regeneration, osteoporosis management, or fracture risk reduction, particularly in postmenopausal women or men with clinically significant bone loss.

Formulation & Quality Specifications:

Delivered as a liquid prefilled pen
Purity: >98% (HPLC-validated)
Storage: 2–8 °C (refrigerated)
Documentation: Full CoA and MSDS available

Concentration:

Frequency:

Dosage (pen clicks):

Duration:

Notes:

0.2 mg/ml, total 3 ml, total 0,6 mg

Daily

1 month

A synthetic form of parathyroid hormone used to treat osteoporosis by stimulating bone growth.